In terms of MPS here what was stated in currently Qtrly:
"Paradigm has now completed clinical studies for MPS I and VI with strong data sets and meaningful endpoints identified to progress the clinical development of iPPS as an adjunctive therapy with a commercial partner"
Previous Qtrly:
"Paradigm is actively seeking to partner this clinical asset to progress iPPS for treatment of MPS toward commercialisation."
PAR Price at posting:
26.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)